Vesiculab’s Post

AM-411 is Altamira Therapeutics' groundbreaking candidate for the treatment of #rheumatoidarthritis. An intraveneously administered nanoparticle based on the OligoPhore™ platform, AM-411 targets p65, one of the main transcriptional regulators of the NF-kB pathway and a key checkpoint in #RA inflammation What are the key differentiating factors of AM-411? - Reduced systemic side effects: Mediators of inflammation play many physiological roles in healthy tissues – AM-411 targets only inflamed tissues - Less likelihood of resistance: Blocking production of an NF-κB component by degrading mRNA to cause less resistance than inhibition of NF-κB Discover more as Altamira hopes to transform treatment paradigms for partients battling RA: https://bit.ly/3JjIBix #Science #RNADelivery #siRNA #mRNA #RNATherapeutics

Our Avanti range of DSPE-PEG (2000) Maleimide enhances drug delivery efficacy as a ligand-mediated targeting agent. Beyond the typical functions of PEG lipids in stabilizing and prolonging the life span of lipid nanoparticles, the maleimide group significantly mitigates off-target effects. Discover our research grade DSPE-PEG(2000) Maleimide https://ow.ly/qsuW50Sy31l

Meet our latest addition to Ncardia’s cell portfolio! Introducing Ncyte® aCardiomyocytes, our newest cell model for cardiovascular research and toxicity studies! Improve in vitro testing of new treatments for atrial arrhythmias or cardiotoxicity assessments with this cell model: 🔶 High purity and chamber specific 🔶 Based on human biology 🔶 Suitable for drug screening Ncyte® aCardiomyocytes can be applied throughout the entire drug discovery pipeline, from extensive screening to crucial decision-making stages in hit-to-lead and lead optimization processes. Learn more here: https://lnkd.in/dyZz_TwZ #stemcell #atrial #cardiacdisease #cardiotoxicity #humanbiology #Ncardia #CardiovascularResearch

Schrödinger’s MALT1 Inhibitor Showcases the Potential of Its Computational Platform and Becomes Its First In-House Clinical Compound | https://lnkd.in/gd9SRikP SGR-1505, the first in-house clinical compound developed at Schrödinger is an oral, allosteric MALT1 inhibitor currently in the clinic for the treatment of mature B cell malignancies. The discovery effort, disclosed at the ACS Spring 2024 meeting, was completed in an impressive 10 months starting from a published scaffold. Over 8 billion compound designs were assessed using Schrödinger’s in-house computational MPO chemistry suite, of which only 129 were synthesized. SGR-1505 showed the ability to resensitize drug-resistant tumors to BTK and BCL-2 inhibitors preclinically and has progressed to a Ph. I clinical trial. Read the full article here | https://lnkd.in/gd9SRikP

Mimicking “The Hercules Hold” of #coagulation #factor-VIII An inherent dysfunction of blood #coagulation #factor VIII leads to Hemophilia A. Prophylactic usage of exogenous #FVIII is of limited use because of frequent IV administrations, short plasma half-life, and development of inhibitory antibodies.   To meet this, a novel antibody-based modality was invented: #Asymmetric #Bispecific IgG #Antibody called #Emicizumab. FIXa recognising arm called Q-chain FX recognising arm called J-chain. In this masterpiece work #Zenjiro #Sampei et al walks us through an evolution of #Emicizumab. The work describes therapeutic development, optimization of the #bispecific antibody by #molecular #engineering to enable large-scale manufacturing of the #bispecific #antibody at clinical grade through following steps,   Identification of Lead #Anti-FIXa/#FX BsAb #Humanization of Lead Chimeric BsAb Improving FVIII-mimetic Activity of BsAb Improving #Pharmacokinetics #Isoelectric Point #Engineering to Facilitate Purification Removing Deamidation Site in the #CDR #Deimmunization of Humanized BsAb by Removing #T-cell #Epitopes   Citation: #Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, et al. (2013) Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity. PLoS ONE 8(2): e57479. doi:10.1371/journal.pone.0057479

#mRNA #boneformation | 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐦𝐑𝐍𝐀 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐬 𝐁𝐨𝐧𝐞 𝐅𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 in vitro and in a murine tibia fracture model Fractures remain a global economic burden, lacking approved osteoanabolic drugs for accelerated healing. This study, led by Anna Laura Nelson, Chiara Mancino, PhD, Xueqin Gao, Joshua Choe, Laura Chubb, Katherine Williams, Molly Czachor, @Ralph Marcucio, Francesca Taraballi, John Cooke, johnny huard, Chelsea Bahney, and Nicole Ehrhart, aims to develop an #mRNA-based therapy that activates the #Wnt/β-catenin pathway, crucial for #endochondral #ossification. Using #FDA-approved #ionizable phospholipids, DLin-MC3-DMA (#MC3) and #SM102, we created lipid nanoparticle (#LNP) formulations. SM-102 LNPs showed superior transfection efficacy in vitro and in a murine tibia fracture model. The β-catenin mRNA therapy encapsulated in SM-102 LNPs increased #bone #formation, showing promise as a novel treatment for enhancing fracture healing. For more check here: https://lnkd.in/eYSMSvhY

SGR-1505: AN ORAL, ALLOSTERIC MALT1 INHIBITOR DEVELOPED BASED ON THE SCHRODINGER AI TECHNOLOGY Schrödinger's effort continues in human testing of his first AI-designed drug against blood cancer, SGR-1505. It is an inhibitor of MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1) Objective achieved in just 10 months, starting from a well-known Novartis scaffold. Using Schrödinger's in-house MPO computational chemistry suite, well over 8 billion potential compounds were evaluated, but only 129 were actually synthesized. https://lnkd.in/dhKzy6b9 Among these, SGR-1505 was selected, a molecule that in preclinical evaluations has demonstrated, both as a single agent and in combination, to be active in B cell neoplasms and has also shown the ability to resensitize drug-resistant tumors to inhibitors. of BTK and BCL-2. The compound has completed Phase I studies on healthy volunteers. He has now moved on to a Phase I study in patients with mature B-cell malignancies. Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger was founded in 1990 and is engaged with customers and collaborators in more than 70 countries. #Schrödinger #MALT1 #AI https://lnkd.in/dwXB8TWE

✒️ Published in the March issue of Anticancer Research, the study in the link below, assessed fisetin's potential in combination with temozolomide for #glioblastoma treatment. 📎 https://lnkd.in/dSxpkkdx ℹ️ Fisetin is a yellow flavonoid found in plants and fruits, known to exhibit cytotoxic properties against glioblastoma cells, inducing apoptosis and DNA damage. 🔬 Results indicate that fisetin induces DNA damage, enhances genotoxic effects, and synergizes with temozolomide, suggesting its potential in adjuvant #cancertherapy. Clinical trials are proposed to further explore fisetin's role in eliminating therapy-induced senescent cells and enhancing the effectiveness of anticancer drugs, particularly for glioblastoma. University Medical Center Mainz, University of Medicine, Pharmacy, Science and Technology "G.E. Palade" of Târgu Mureș, International Institute of Anticancer Research #anticancer #cancerresearch #flavonoids

Introducing HYBRID-ON: A Breakthrough in Oligonucleotide Detection! At ADViRNA, we’re proud to unveil HYBRID-ON, our innovative ELISA-based assay designed to tackle the challenges of detecting therapeutic oligonucleotides. Our HYBRID-ON assay changes the game with: ✅ Sequence-agnostic detection for various oligonucleotides. ✅ High sensitivity (1-1000 fmol), perfect for small sample sizes. ✅ Adaptability to multiple sample types like cultured cells, plasma, and tissues. ✅ Optimized for chemically modified oligonucleotides. Whether you’re investigating siRNA, ASOs, or other therapeutic oligonucleotides, HYBRID-ON simplifies and enhances the detection process. Want to learn more about how HYBRID-ON can improve your research? Contact us today! https://lnkd.in/erNW4Aer #RNAi #OligonucleotideResearch #siRNA #ELISA #ADViRNA #Biodistribution #HybridOn #Therapeutics #Innovation

🫀Organ-on-a-chip is increasingly playing an important role in the research process of improving therapies and developing new pharmaceuticals. 👩🔬The researchers from University of Latvia and Latvia Riga East University Hospital has developed a pancreatic ductal adenocarcinoma (PDAC) organ on a chip system, which simulated the tumor microenvironment in the chip and is suitable for drug sensitivity and secretion biomarker research. The chip could serve as a platform for functional precision medicine application and multi organ chip development. 💉To avoid the shear stress fluctuations of common peristaltic pumps, researchers specifically chose the ISPLab10 syringe pump to offer the advantage of controlled constant flow to mimic blood vessel perfusion. 👀Check this out: https://lnkd.in/ejGuJg8b 【Personalized PDAC chip with functional endothelial barrier for tumour biomarker detection: A platform for precision medicine applications】 #SyringePump #ISPLab #OrganOnAChip